Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring gemcitabine, 5-fluorouracil, 5-FU, unresectable pancreatic cancer, non-metastatic pancreatic cancer
Eligibility Criteria
Inclusion Criteria: Histologic confirmation of locally unresectable pancreatic adenocarcinoma. Patients with either measurable of evaluable disease are eligible. Unresectable, non-metastatic tumors. Unresectable patients include those with local extension of the tumor into adjacent structures and/or nodal metastasis. Total bilirubin < 2.0 mg/dl AST < 3x ULN Serum creatinine < 2.0 mg/dl WBC > 3,000/mm3 Platelets > 100,000/mm3 ECOG performance status < or = to 2 Life expectancy of greater than 12 weeks Exclusion Criteria: Evidence of peritoneal seeding by malignancy Prior radiation therapy or chemotherapy for pancreatic cancer Myocardial infarction in the past 6 months Major surgery in past two weeks Uncontrolled serious medical or psychiatric illness Pregnant or lactating women Concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
Sites / Locations
- Massachusetts General Hospital
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
Arms of the Study
Arm 1
Experimental
5-FU/gemcitabine/RT